Clinical presentation, diagnosis and management of multisystem inflammatory syndrome in children (MIS-C): a systematic review

• Published in: BMJ paediatrics open 2024-06, Vol.8 (1), p.e002344
• Main Authors: Abbas, Qalab, Ali, Haider, Amjad, Fatima, Hussain, Muhammad Zaid Hamid, Rahman, Abdu R, Khan, Maryam Hameed, Padhani, Zahra A, Abbas, Fatima, Imam, Danyal, Alikhan, Zuviya, Belgaumi, Sameer M., Mohsin, Shazia, Sattar, Faiza, Siddiqui, Arsalan, Lassi, Zohra S, Das, Jai K
• Format: Article
• Language: English
• Subjects: Child; COVID-19; COVID-19 - complications; COVID-19 - diagnosis; COVID-19 - mortality; COVID-19 - therapy; Cross-sectional studies; Data collection; Disease; Hospitals; Humans; Industrialized nations; Infectious Diseases; Intensive care; Medical diagnosis; Medical laboratories; Mortality; Multisystem inflammatory syndrome in children; Patients; Pediatrics; Severe acute respiratory syndrome coronavirus 2; Systematic review; Systemic Inflammatory Response Syndrome - diagnosis; Systemic Inflammatory Response Syndrome - mortality; Systemic Inflammatory Response Syndrome - therapy
• ISSN: 2399-9772; 2399-9772
• DOI: 10.1136/bmjpo-2023-002344

BackgroundKnowledge about multisystem inflammatory syndrome in children (MIS-C) is evolving, and evidence-based standardised diagnostic and management protocols are lacking. Our review aims to summarise the clinical and diagnostic features, management strategies and outcomes of MIS-C and evaluate the variances in disease parameters and outcomes between high-income countries (HIC) and middle-income countries (MIC).MethodsWe searched four databases from December 2019 to March 2023. Observational studies with a sample size of 10 or more patients were included. Mean and prevalence ratios for various variables were pooled by random effects model using R. A mixed generalised linear model was employed to account for the heterogeneity, and publication bias was assessed via funnel and Doi plots. The primary outcome was pooled mean mortality among patients with MIS-C. Subgroup analysis was conducted based on the income status of the country of study.ResultsA total of 120 studies (20 881 cases) were included in the review. The most common clinical presentations were fever (99%; 95% CI 99.6% to 100%), gastrointestinal symptoms (76.7%; 95% CI 73.1% to 79.9%) and dermatological symptoms (63.3%; 95% CI 58.7% to 67.7%). Laboratory investigations suggested raised inflammatory, coagulation and cardiac markers. The most common management strategies were intravenous immunoglobulins (87.5%; 95% CI 82.9% to 91%) and steroids (74.7%; 95% CI 68.7% to 79.9%). Around 53.1% (95% CI 47.3% to 58.9%) required paediatric intensive care unit admissions, and overall mortality was 3.9% (95% CI 2.7% to 5.6%). Patients in MIC were younger, had a higher frequency of respiratory distress and evidence of cardiac dysfunction, with a longer hospital and intensive care unit stay and had a higher mortality rate than patients in HIC.ConclusionMIS-C is a severe multisystem disease with better mortality outcomes in HIC as compared with MIC. The findings emphasise the need for standardised protocols and further research to optimise patient care and address disparities between HIC and MIC.PROSPERO registration numberCRD42020195823.